Cover Image
市場調查報告書

類風濕性關節炎治療藥的全球市場 2016-2026年

Rheumatoid Arthritis (RA) Drugs Market 2016-2026

出版商 Visiongain Ltd 商品編碼 220557
出版日期 內容資訊 英文 162 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
類風濕性關節炎治療藥的全球市場 2016-2026年 Rheumatoid Arthritis (RA) Drugs Market 2016-2026
出版日期: 2016年07月26日 內容資訊: 英文 162 Pages
簡介

全球類風濕性關節炎 (RA) 治療藥市場規模,2020年達到346億美元。

本報告提供全球類風濕性關節炎 (RA) 治療藥市場相關調查分析,各主要產品的收益預測,各地區趨勢,研究開發,市場競爭和機會等彙整資料,為您概述為以下內容。

第1章 調查概要

第2章 所謂類風濕性關節炎

  • 所謂類風濕性關節炎的原因
  • 疾病怎麼發展
  • 檢驗方法
  • RA能治療嗎
  • 臨床實驗所使用的評價標準
  • RA的治療方法

第3章 全球類風濕性關節炎治療藥市場

  • 全球類風濕性關節炎市場
  • 全球RA治療藥市場:收益預測
  • 全球RA治療藥市場區隔:收益預測
  • RA的非生技藥品
    • NSAID:收益預測
    • 合成DMARD:收益預測
    • 其他:收益預測
  • RA的生技藥品:收益預測

第4章 RA市場上的主要治療藥

  • RA市場上的主要治療藥
  • Humira
    • Adalimumab的生技仿製藥
    • Humira:收益預測
  • Enbrel
  • Remicade
  • Rituxan
  • Simponi
  • Orencia
  • Actemra
  • Cimzia
  • Celebrex
  • Xeljanz
  • Arcoxia

第5章 風濕的主要國家市場

  • 主要國家市場
  • 主要國家市場:收益、市場佔有率的皮革
  • 主要國家市場:收益預測
  • 美國:順利的經濟與大規模的患者人口使RA治療藥市場上處於優勢
    • 美國的RA治療藥市場:收益預測
  • 維持日本:第二大市場
    • 日本的RA治療藥市場:收益預測
  • EU5個國家持有18%的市場佔有率
    • 德國的RA治療藥市場:收益預測
    • 法國RA治療藥市場:收益預測
    • 義大利RA治療藥市場:收益預測
    • 西班牙RA治療藥市場:收益預測
    • 英國RA治療藥市場:收益預測
  • 中國:經濟發展市場佔有率擴大
    • 中國的RA治療藥市場:收益預測
  • 印度:人口增加促進成長
    • 印度的RA治療藥市場:收益預測
  • 俄羅斯:混亂的經濟抑制擴大
    • 俄羅斯的RA治療藥市場:收益預測
  • 巴西:國內醫藥品製造的重視
    • 巴西的RA治療藥市場:收益預測

第6章 類風濕性關節炎的研發產品線

  • IL-6抑制劑成為TNF抑制劑的對手
  • JAK抑制劑:有前途的試劑類
  • BTK抑制劑
  • GM-CSF抑制劑

第7章 類風濕性關節炎治療藥市場上的主要企業

  • 主要企業的簡介
  • AbbVie:確保Humira的複數專利
  • Roche:第2名企業
  • Johnson & Johnson:對於Sirukumab的大期待
  • Amgen:Enbrel銷售在美國受保護
  • Pfizer:活躍開發生技仿製藥
  • Merck & Co.: REMICADE的銷售額減少
  • BMS:探索ORENCIA其他適應症
  • UCB:依賴Cimzia收入

第8章 類風濕性關節炎治療藥市場定性分析

  • 類風濕性關節炎市場優勢、弱點
  • 類風濕性關節炎市場面臨的機會、威脅
  • 類風濕性關節炎市場STEP分析

第9章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0131

Title:
Rheumatoid Arthritis (RA) Drugs Market 2016-2026
Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs and Other Agents) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets (US, Japan the EU5 and BRIC).

Rheumatoid Arthritis - New Study Showing You Those Drugs' Commercial Potentials

Where is the arthritic treatments market heading? Visiongain's updated report gives you forecasted revenues to 2026 for drugs treating rheumatoid arthritis (RA). There you find R&D trends, sales forecasting and commercial opportunities.

Our study lets you assess sales data and predictions for the world RA medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.

Read on to scan features of that industry, find what drives it, and see what its future market could be worth.

Forecasts and other analyses to help you assess the RA drugs market

Our report shows you revenue forecasts to 2026, sales results, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and R&D. Our 161 page report gives 67 tables and 65 charts to help your work.

With our study you can stay ahead in knowledge, benefiting your research, analyses, plans and decisions. There you find trends, innovations and opportunities for treating rheumatoid arthritis.

There is rising need worldwide for drugs treating arthritis. Our work helps you find markets, products and developments with most commercial promise.

The following sections show how you benefit from our new study.

Discover sales predictions for that overall world market and submarkets

Along with revenue prediction for the overall world market for treating RA, our work shows you forecasts to 2026 for two main submarkets:

  • Biologics (biological drugs, e.g. monoclonal antibodies [mAbs])
  • Non-biologics (other therapeutic molecules).

For the non-biologics submarket, you get three further revenue breakdowns to 2026:

  • NSAIDs
  • sDMARDs
  • Others agents (grouped).

From 2016, how will the RA drugs market expand? Which parts will most prosper? For anti-rheumatic medicines, our report helps you identify sales potentials and find opportunities.

Our investigation also discusses what stimulates and restrains business. There you explore dynamics of that industry, also seeing what products can achieve the most success.

See revenue forecasts for 11 leading drugs

Our study forecasts revenues of 11 leading products for rheumatoid arthritis, including the following drugs:

  • Humira (adalimumab)
  • Enbrel (etanercept)
  • Remicade (infliximab)
  • Rituxan (rituximab)
  • Actemra (tocilizumab)
  • Orencia (abatacept).

With our analysis you discover how high sales can go, to 2026, finding drugs and years with highest predicted revenues and growth. You also assess competition, exploring trends, challenges and opportunities.

Our analysis also divides its overall world RA revenue forecast into geographical segments.

What sales and growth potentials for leading countries?

In developed and developing countries - especially India and China - there remain many opportunities for expanded selling of drugs to treat rheumatoid arthritis. Our study shows you individual revenue forecasts to 2026 for eleven national markets:

  • US
  • Japan
  • Germany, France, UK, Italy and Spain (EU5)
  • Brazil, Russia, India and China (BRIC).

That way you discover progress and outlooks. You assess the industry's future - hear about developments and find what they mean.

Our analysis shows revenue growth will occur in established pharma markets and in emerging countries. In particular, product launches from 2016 to 2026 will change anti-rheumatic drug prescribing and the commercial landscape. See what is possible.

Research and development - assess innovation, trends and possibilities

What about R&D - the pipeline for new RA drugs? Our study shows you developmental trends for these agents and others:

  • IL-6 inhibitors
  • JAK inhibitors
  • BTK inhibitors.

In our work you assess innovations, hearing about developments and finding their meaning. For large companies and specialty pharma firms there exist many opportunities in treating rheumatoid arthritis. Assess those firms' prospects.

Our study explains, also discussing forces affecting those companies and their market.

What affects the anti-arthritic drugs industry and market?

Our report discusses issues and events affecting that industry and market from 2016, including these developments:

  • Biologics, including biosimilars
  • Corticosteroids and other agents (e.g. JAK inhibitors)
  • Demand for more-efficacious and better-tolerated drugs
  • Need for less invasive routes of administration - drug delivery
  • Biosimilars and generics as challengers to original-branded medicines
  • Adalimumab, etanercept, infliximab and rituximab biosimilars
  • Regional variability in biosimilar approval.

That way you explore technological, economic, social and political questions, assessing outlooks for that business.

Our investigation also lets you analyse the RA treatment industry's strengths, weaknesses, opportunities and threats. Discover what the future holds.

Leading companies and 2020 market value

What happens next? Our study predicts the overall world market for those anti-arthritic drugs will reach $34.6bn in 2020. From 2016 sales will rise.

Our analyses show you what products and organisations hold greatest potential, including these leading companies:

  • AbbVie
  • Roche
  • J&J
  • Amgen
  • Pfizer
  • Merck & Co.

Prospects for arthritic R&D are encouraging, and from 2016 there will arise opportunities, including product launches. Our work shows you technological, clinical and commercial possibilities, helping you stay ahead in knowledge.

6 main ways Rheumatoid Arthritis (RA) Drugs Market 2016-2026 helps your work

In particular our investigation gives you the following knowledge to help your research, plans, decisions and presentations:

  • Revenues to 2026 for the overall rheumatoid arthritis drugs market and for 5 world-level submarkets - discover sales and growth potentials
  • Revenues to 2026 for 11 leading products - find sales outlooks for top brands, seeing how they can compete and succeed
  • Forecasts to 2026 for the US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - see national sales potentials, finding the best regions for revenues and sales growth
  • R&D for treating rheumatoid arthritis - investigate technologies and progress, assessing medical and commercial possibilities
  • Discussions of leading companies, including profiles of 8 leading players - hear about strategies, capabilities, results and outlooks
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages.

That investigation, by our in-house analysts in the UK, gives knowledge to benefit your work. Our study shows information you find nowhere else, helping you succeed.

Independent data to benefit your authority on treating rheumatoid arthritis

Our report gives you independent analysis. It shows competitive intelligence found only in our study, helping you assess technological and commercial potentials.

With that report you are less likely to fall behind in information or miss opportunity. Discover how you could benefit your analyses, plans and decisions, also saving time and helping your influence.

So explore the future of drugs treating rheumatoid arthritis. In our study you find data, trends, opportunities and sales predictions. Stay ahead by getting our new report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Rheumatoid Arthritis Overview
  • 1.2. Rheumatoid Arthritis Market Segmentation
  • 1.3. Why You Should Read this Report
  • 1.4. How this Report Delivers
  • 1.5. Main Questions Answered by this Report
  • 1.6. Who is this Report for?
  • 1.7. Research and Analysis Methods
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Some Associated Reports
  • 1.10. About Visiongain

2. What is Rheumatoid Arthritis?

  • 2.1. What Causes Rheumatoid Arthritis?
  • 2.2. How Does the Disease Develop?
  • 2.3. How Can It Be Monitored?
  • 2.4. Can RA Be Cured?
  • 2.5. Performance Criteria Used in Clinical Trials
    • 2.5.1. ACR Criteria For Drug Efficacy
    • 2.5.2. HAQ-DI Measures Daily Activities
    • 2.5.3. mSS Assesses Disease on X-Ray
    • 2.5.4. DAS28 For Disease Severity
  • 2.6. How is RA Treated?
    • 2.6.1. Biologic DMARDs Are the Dominant Source of Revenue
    • 2.6.2. Synthetic DMARDs are the Mainstay of Treatment
    • 2.6.3. Others
      • 2.6.3.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 2.6.3.2. Corticosteroids for Rapid Anti-Inflammatory Effect
      • 2.6.3.3. Analgesics for Rapid Pain Relief

3. World Drug Market for Rheumatoid Arthritis 2016-2026

  • 3.1. The Global Rheumatoid Arthritis Market, 2015
  • 3.2. The Global RA Drugs Market: Revenue Forecast 2015-2026
  • 3.3. The Global RA Drugs Market Segments: Revenue Forecast 2015-2026
  • 3.4. Non-Biologics for RA
    • 3.4.1. NSAIDs: Revenue Forecast, 2015-2026
    • 3.4.2. Synthetic DMARDs: Revenue Forecast, 2015-2026
    • 3.4.3. Others: Revenue Forecast, 2015-2026
  • 3.5. Biologics for RA: Revenue Forecast 2015-2026

4. Leading Drugs in the RA Market 2016-2026

  • 4.1. The Main Drugs in the RA Market, 2015
  • 4.2. Humira: A Major Source of Revenue for AbbVie
    • 4.2.1. Adalimumab Biosimilars
    • 4.2.2. Humira: Revenue Forecast 2015-2026
  • 4.3. Enbrel: Amgen's Revenue Protected Until 2028
    • 4.3.1. Etanercept Biosimilars
    • 4.3.2. Enbrel: Revenue Forecast 2015-2026
  • 4.4. Remicade: Facing Significant Competition from Biosimilars
    • 4.4.1. Infliximab Biosimilars
    • 4.4.2. Remicade: Revenue Forecast 2015-2026
  • 4.5. Rituxan: Facing Declining Market Share
    • 4.5.1. Rituximab Biosimilars
    • 4.5.2. Rituxan: Revenue Forecast 2015-2026
  • 4.6. Simponi: Market Share Remaining Stable
    • 4.6.1. Simponi: Revenue Forecast 2015-2026
  • 4.7. Orencia: Additional Indications Being Explored
    • 4.7.1. Abatacept Biosimilars
    • 4.7.2. Orencia: Revenue Forecast 2015-2026
  • 4.8. Actemra: First IL-6R Inhibitor Approved for RA
    • 4.8.1. Tocilizumab Biosimilars
    • 4.8.2. Actemra: Revenue Forecast 2015-2026
  • 4.9. Cimzia: Reliable Source of Income for UCB
    • 4.9.1. Certolizumab Biosimilars
    • 4.9.2. Cimzia: Revenue Forecast 2015-2026
  • 4.10. Celebrex: Facing Generic Competition
    • 4.10.1. Celebrex: Revenue Forecast 2015-2026
  • 4.11. Xeljanz: Good Opportunity for Revenue Growth
    • 4.11.1. Xeljanz: Revenue Forecast 2015-2026
  • 4.12. Arcoxia: Sales Revenue Already Declining
    • 4.12.1. Arcoxia: Revenue Forecast 2015-2026

5. Leading National Markets for Rheumatoid Arthritis 2016-2026

  • 5.1. The Leading National Markets in 2015
  • 5.2. The Leading National Markets: Comparison of Revenues and Market Shares to 2026
  • 5.3. The Leading National Markets: Grouped Revenue Forecasts 2016-2026
  • 5.4. The US: Prosperous Economy and Large Patient Population Enables it to Dominate the RA Drugs Market
    • 5.4.1. The US RA Drug Market: Revenue Forecast 2016-2026
  • 5.5. Japan: Remains the Second Largest National Market
    • 5.5.1. The RA Drug Market in Japan: Revenue Forecast 2016-2026
  • 5.6. The EU5 Have 18% Market Share
    • 5.6.1. The RA Drug Market in Germany: Revenue Forecast 2016-2026
    • 5.6.2. The RA Drug Market in France: Revenue Forecast 2016-2026
    • 5.6.3. The RA Drug Market in Italy: Revenue Forecast 2016-2026
    • 5.6.4. The RA Drug Market in Spain: Revenue Forecast 2016-2026
    • 5.6.5. The RA Drug Market in the UK: Revenue Forecast 2016-2026
  • 5.7. China: Expanding Economy with Increasing Market Share
    • 5.7.1. The RA Drug Market in China: Revenue Forecast 2016-2026
  • 5.8. India: Expanding Population Driving Growth
    • 5.8.1. The RA Drug Market in India: Revenue Forecast 2016-2026
  • 5.9. Russia: Expansion Held Back by Troubled Economy
    • 5.9.1. The RA Drug Market in Russia: Revenue Forecast 2016-2026
  • 5.10. Brazil: Focus on Domestic Drug Manufacturing
    • 5.10.1. The RA Drug Market in Brazil: Revenue Forecast 2016-2026

6. Rheumatoid Arthritis R&D Pipeline 2016

  • 6.1. IL-6. Inhibitors Could Rival TNF-Inhibitors
    • 6.1.1. Sarilumab: Already Filed With FDA
    • 6.1.2. Sirukumab: Expected to File in Q3, 2016
    • 6.1.3. Olokizumab: Promising Phase 2 Data
    • 6.1.4. Clazakizumab: Alder Now Collaborating with Vitaeris
  • 6.2. JAK Inhibitors: A Promising Class of Agents
    • 6.2.1. Baricitinib: Potential Competitor to Xeljanz
    • 6.2.2. Peficitinib: Selective JAK-3 Inhibitor From Astellas
    • 6.2.3. ABT-494: Selective JAK-1 Inhibitor From AbbVie
    • 6.2.4. Filgotinib: Following AbbVie's Withdrawal, Galapagos Now Working with Gilead
  • 6.3. BTK Inhibitors
    • 6.3.1. BMS-986142: Well Tolerated in Phase 1
    • 6.3.2. HM71224: Collaboration with Eli Lilly
  • 6.4. GM-CSF Inhibitor
    • 6.4.1. GSK 3196165: Potential Role in Early Disease

7. Leading Companies in the Rheumatoid Arthritis Drugs Market, 2016

  • 7.1. Introduction to the Leading Companies
  • 7.2. AbbVie: Secured Multiple Patents for Humira
  • 7.3. Roche: Second-Leading Company
  • 7.4. Johnson & Johnson: High Hopes for Sirukumab
  • 7.5. Amgen: Enbrel Sales Protected in the US
  • 7.6. Pfizer: Actively Developing Biosimilars
  • 7.7. Merck & Co.: Remicade Sales in Decline
  • 7.8. BMS: Exploring Additional Indications for Orencia
  • 7.9. UCB: Reliant on Cimzia Revenue

8. Qualitative Analysis of the Rheumatoid Arthritis Drugs Market 2016-2026

  • 8.1. Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2016
    • 8.1.1. Number of Elderly Patients Expected to Rise
    • 8.1.2. Biologics Already Recognised as a Valuable Part of Treatment
    • 8.1.3. Biologics Used in RA Often Have Multiple Indications
    • 8.1.4. Some Patients Have an Inadequate Treatment Response
    • 8.1.5. Efficacy of Drugs Can Diminish Over Time
  • 8.2. Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2016-2026
    • 8.2.1. Need for Effective Drugs With Better Safety Profiles
    • 8.2.2. Need for Less Invasive Routes of Administration
    • 8.2.3. High Number of Products Will Saturate Market
    • 8.2.4. Competition from Biosimilars Will Increase
  • 8.3. Social, Technological, Economic and Political Factors Affecting the Rheumatoid Arthritis Market (STEP Analysis), 2016-2026
    • 8.3.1. Social Factors Influencing the Rheumatoid Arthritis Market
    • 8.3.2. Technological Factors Influencing the Rheumatoid Arthritis Market
    • 8.3.3. Economic Factors Influencing the Rheumatoid Arthritis Market
    • 8.3.4. Political Factors Influencing the Rheumatoid Arthritis Market
      • 8.3.4.1. Government Pressure to Control Costs
      • 8.3.4.2. Inter-country Variability in Biosimilar Approval Process

9. Conclusions

  • 9.1. Global Market for RA Drugs Will Contract After 2018
  • 9.2. Biologics Will Remain the Dominant Drug Class but their Market Share Will Drop By 10%
  • 9.3. Enbrel Will Overtake Humira as the Leading Drug
  • 9.4. US Will Remain the Dominant Market
  • 9.5. Trends in the RA Drugs Market

List of Tables

  • Table 2.1: Biologic Agents and Mechanism of Action
  • Table 3.1: The RA Drugs Market by Submarket, 2015
  • Table 3.2: The Drugs Market for RA: Revenue ($m) Forecast, 2015-2026
  • Table 3.3: The RA Drugs Market Segments: Revenue ($m) Forecast, 2015-2026
  • Table 3.4: Non-Biologics for RA: Revenue ($m) Forecasts by Segment, 2015-2026
  • Table 3.5: NSAIDs: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 3.6: sDMARDs: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 3.7: Others: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 3.8: Biologics for RA: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 4.1: The Main Drugs in the RA Market: Revenue ($m) and Market Share (%), 2015
  • Table 4.2: The Main Drugs in the RA Market: Revenue ($m) Forecasts, 2015-2021
  • Table 4.3: The Main Drugs in the RA Market: Revenue ($m) Forecasts, 2022-2026
  • Table 4.4: Humira: Key Facts
  • Table 4.5: Adalimumab Biosimilars: Current Status, 2016
  • Table 4.6: Humira: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.7: Enbrel: Key Facts
  • Table 4.8: Etanercept Biosimilars : Current Status, 2016
  • Table 4.9: Enbrel: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.10: Remicade: Key Facts
  • Table 4.11: Infliximab Biosimilars: Current Status, 2016
  • Table 4.12: Remicade: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.13: Rituxan: Key Facts
  • Table 4.14: Rituximab Biosimilars: Current Status, 2016
  • Table 4.15: Rituxan: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.16: Simponi: Key Facts
  • Table 4.17: Simponi: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.18: Orencia: Key Facts
  • Table 4.19: Orencia: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.20: Actemra: Key Facts
  • Table 4.21: Actemra: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.22: Cimzia: Key Facts
  • Table 4.23: Cimzia: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.24: Celebrex: Key Facts
  • Table 4.25: Celebrex: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.26: Xeljanz: Key Facts
  • Table 4.27: Xeljanz: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.28: Arcoxia: Key Facts
  • Table 4.29: Arcoxia: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.1: The Leading National Markets for RA: Revenue ($m) and Market Share (%), 2015
  • Table 5.2: RA Drugs: Market Share (%) by Country, 2015 and 2026
  • Table 5.3: RA Drugs: Revenue ($m) Forecast by Country, 2015-2026
  • Table 5.4: The US RA Drug Market: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.5: The RA Drug Market in Japan: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.6: The EU5 RA Drug Markets: Revenue ($m) Forecast, 2015-2026
  • Table 5.7: The RA Drug Market in Germany: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.8: The RA Drug Market in France: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.9: The RA Drug Market in Italy: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.10: The RA Drug Market in Spain: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.11: The RA Drug Market in the UK: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.12: The RA Drug Market in China: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.13: The RA Drug Market in India: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.14: The RA Drug Market in Russia: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.15: The RA Drug Market in Brazil: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 6.1: Pipeline R&D Products, 2016
  • Table 7.1: Leading Companies in the RA Drug Market: Revenue ($m) and Market Share (%), 2015
  • Table 7.2: AbbVie: Breakdown of Revenue ($m,%) by RA Drug, 2015
  • Table 7.3: Roche: Breakdown of Revenue ($m,%) by RA Drug, 2015
  • Table 7.4: J&J: Breakdown of Revenue ($m,%) by RA Drug, 2015
  • Table 7.5: Amgen: Breakdown of Revenue ($m,%) by RA Drug, 2015
  • Table 7.6: Pfizer: Breakdown of Revenue ($m,%) by RA Drug, 2015
  • Table 7.7: Merck & Co.: Breakdown of Revenue ($m,%) by RA Drug, 2015
  • Table 7.8: BMS: Breakdown of Revenue ($m,%) by RA Drug, 2015
  • Table 7.9: UCB: Breakdown of Revenue ($m,%) by RA Drug, 2015
  • Table 8.1: Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2016
  • Table 8.2: Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2016-2026
  • Table 8.3: Social, Technological, Economic and Political Factors Influencing the RA Market, 2016-2026
  • Table 9.1: Drivers and Restraints of the RA Drugs Market, 2016-2026

List of Figures

  • Figure 1.1: Main Segments and Sub-Segments of the Rheumatoid Arthritis Market, 2016
  • Figure 3.1: The RA Drugs Market: Market Share (%) by Submarket, 2015
  • Figure 3.2: The Drugs Market for RA: Revenue ($m) Forecast, 2015-2026
  • Figure 3.3: The RA Drugs Market Segments: Revenue ($m) Forecast, 2015-2026
  • Figure 3.4: The RA Drugs Market: Market Share (%) by Segment, 2021
  • Figure 3.5: The RA Drugs Market: Market Share (%) by Segment, 2026
  • Figure 3.6: Non-Biologics for RA: Revenue ($m) Forecasts by Segment, 2015-2026
  • Figure 3.7: Non-Biologics for RA: Market Share (%), 2015
  • Figure 3.8: Non-Biologics for RA: Market Share (%), 2021
  • Figure 3.9: Non-Biologics for RA: Market Share (%), 2026
  • Figure 3.10: NSAIDs: Revenue ($m) Forecast, 2015-2026
  • Figure 3.11: sDMARDs: Revenue ($m) Forecast, 2015-2026
  • Figure 3.12: Others: Revenue ($m) Forecast, 2015-2026
  • Figure 3.13: Biologics for RA: Revenue ($m) Forecast, 2015-2026
  • Figure 4.1: The Main Drugs in the RA Market: Market Shares (%), 2015
  • Figure 4.2: Humira: Revenue ($m) Forecast, 2015-2026
  • Figure 4.3: Enbrel: Revenue ($m) Forecast, 2015-2026
  • Figure 4.4: Remicade: Revenue ($m) Forecast, 2015-2026
  • Figure 4.5: Rituxan: Revenue ($m) Forecast, 2015-2026
  • Figure 4.6: Simponi: Revenue ($m) Forecast, 2015-2026
  • Figure 4.7: Orencia: Revenue ($m) Forecast, 2015-2026
  • Figure 4.8: Actemra: Revenue ($m) Forecast, 2015-2026
  • Figure 4.9: Cimzia: Revenue ($m) Forecast, 2015-2026
  • Figure 4.10: Celebrex: Revenue ($m) Forecast, 2015-2026
  • Figure 4.11: Xeljanz: Revenue ($m) Forecast, 2015-2026
  • Figure 4.12: Arcoxia: Revenue ($m) Forecast, 2015-2026
  • Figure 5.1: RA: Market Share (%) by Country, 2015
  • Figure 5.2: RA: Market Share (%) by Country, 2026
  • Figure 5.3: The US RA Drug Market: World Market Share (%), 2015
  • Figure 5.4: The US RA Drug Market: Revenue ($m) Forecast, 2015-2026
  • Figure 5.5: The RA Drug Market in Japan: World Market Share (%), 2015
  • Figure 5.6: The RA Drug Market in Japan: Revenue ($m) Forecast, 2015-2026
  • Figure 5.7: The EU5 RA Drug Markets: World Market Share (%), 2015
  • Figure 5.8: The EU5 RA Drug Markets: Revenue ($m) Forecast 2015-2026
  • Figure 5.9: The RA Drug Market in Germany: World Market Share (%), 2015
  • Figure 5.10: The RA Drug Market in Germany: Revenue ($m) Forecast 2015-2026
  • Figure 5.11: The RA Drug Market in France: World Market Share (%), 2015
  • Figure 5.12: The RA Drug Market in France: Revenue ($m) Forecast, 2015-2026
  • Figure 5.13: The RA Drug Market in Italy: World Market Share (%), 2015
  • Figure 5.14: The RA Drug Market in Italy: Revenue ($m) Forecast, 2015-2026
  • Figure 5.15: The RA Drug Market in Spain: World Market Share (%), 2015
  • Figure 5.16: The RA Drug Market in Spain: Revenue ($m) Forecast, 2015-2026
  • Figure 5.17: The RA Drug Market in the UK: World Market Share (%), 2015
  • Figure 5.18: The RA Drug Market in the UK: Revenue ($m) Forecast, 2015-2026
  • Figure 5.19: The RA Drug Market in China: World Market Share (%), 2015
  • Figure 5.20: The RA Drug Market in China: Revenue ($m) Forecast, 2015-2026
  • Figure 5.21: The RA Drug Market in India: World Market Share (%), 2015
  • Figure 5.22: The RA Drug Market in India: Revenue ($m) Forecast, 2015-2026
  • Figure 5.23: The RA Drug Market in Russia: World Market Share (%), 2015
  • Figure 5.24: The RA Drug Market in Russia: Revenue ($m) Forecast, 2015-2026
  • Figure 5.25: The RA Drug Market in Brazil: World Market Share (%), 2015
  • Figure 5.26: The RA Drug Market in Brazil: Revenue ($m) Forecast, 2015-2026
  • Figure 7.1: Leading Companies in the RA Drug Market: Market Share (%), 2015
  • Figure 7.2: AbbVie: Breakdown of Revenue (%) by RA Drug, 2015
  • Figure 7.3: Roche: Breakdown of Revenue (%) by RA Drug, 2015
  • Figure 7.4: J&J: Breakdown of Revenue (%) by RA Drug, 2015
  • Figure 7.5: Amgen: Breakdown of Revenue (%) by RA Drug, 2015
  • Figure 7.6: Pfizer: Breakdown of Revenue (%) by RA Drug, 2015
  • Figure 7.7: Merck & Co: Breakdown of Revenue (%) by RA Drug, 2015
  • Figure 7.8: BMS: Breakdown of Revenue (%) by RA Drug, 2015
  • Figure 7.9: UCB: Breakdown of Revenue (%) by RA Drug, 2015
  • Figure 9.1: RA Drugs Market: Comparison of Revenue ($m) Forecasts for Total Market and Market for RA Indication, 2015-2026
  • Figure 9.2: RA Drugs Market: Comparison of Revenue ($m) Forecasts for Biologic and Non-Biologic Segments, 2015-2026
  • Figure 9.3: The Leading Drugs in the RA Market: Revenue ($m) Forecasts, 2015, 2021, 2026
  • Figure 9.4: The Leading National Markets for RA Drugs: Revenue ($m) Forecasts, 2015, 2021, 2026

Companies Listed

  • Abbott Laboratories
  • AbbVie Inc
  • Ablynx NV
  • Agência Nacional de Vigilância Sanitária (ANVISA) Brazil
  • Alder Biopharmaceuticals
  • American College of Rheumatology
  • Amgen Inc
  • Astellas Pharma
  • Baxalta
  • Biocad
  • Biocon
  • Biogen
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • Can-Fite BioPharma
  • Celltrion Inc
  • Chugai Pharmaceutical Co
  • Cipla
  • Coherus BioSciences
  • Committee for Medicinal Products for Human Use (CHMP)
  • Covagen
  • Daiichi Sankyo
  • Dr. Reddy's Laboratories
  • Drug Effectiveness Review Project, US
  • Eli Lilly
  • European Medicines Agency (EMA)
  • Epirus Biopharmaceuticals
  • European Commission
  • F Hoffman-La Roche AG (Roche)
  • Food and Drug Administration (FDA)
  • Fujifilm Corporation
  • Galapagos NV
  • Genentech
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Hanmi Pharmaceutical Co
  • Hanwha Biologics
  • Hanwha Chemical Corp
  • Hetero Healthcare
  • Incyte Corporation
  • Institut fur Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Germany
  • Institute for Clinical and Economic Review, US
  • Intas Pharmaceuticals
  • Janssen Biologics
  • Janssen Biotech
  • Janssen Pharmaceutical Companies
  • Johnson & Johnson (J&J)
  • Kyowa Hakko Kirin Co
  • LG Life Sciences
  • Merck & Co.
  • Merck KGaA
  • Merck, Sharp & Dohme Corp (MSD)
  • Ministry of Food and Drug Safety, South Korea
  • Ministry of Health, Italy
  • Ministry of Health, Labor and Welfare (MHLW), Japan
  • Mitsubishi Tanabe Pharma Corporation
  • Momenta Pharmaceuticals
  • MorphoSys
  • Mycenax Biotech
  • Mylan
  • National Health Service (NHS), UK
  • National Institute for Health and Care Excellence (NICE), UK
  • National Institute for Health Research (NIHR), UK
  • Nichi-Iko Pharmaceutical Co
  • Novartis International
  • Oncobiologics
  • Pfizer
  • Protalix Biotherapeutics
  • Regeneron Pharmaceuticals
  • Samsung Bioepis Co
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • Servizio Sanitario Nazionale (SSN), Italy
  • Shanghai Celgen Bio-Pharmaceutical Co
  • Shanghai CP Guojian Pharmaceutical Co
  • Simcere Pharmaceutical Group
  • Sistema Único de Saúde (SUS) Brazil
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical Co
  • TSH Biopharm Corporation
  • UCB
  • US Patent Office
  • Vitaeris
  • World Bank
  • World Health Organization (WHO)
  • Zydus Cadila
Back to Top